Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
21 76150
.
.
~ DESCRIPTION
A METHOD FOR DETECTING BLOOD COMPONENT AND
A KI~ USING THE METHOD
Technoloqical Field
The present invention relates to a method for
specifically detecting blood component derived from human
and, more particularly, to a method for detecting a~blood
component capable of detecting minute bleeding in
digestive tract for the purposes of screening, for
example, the screening of colorectal cancer and the like,
and a kit using this detection method.
Backqround Art
Detection of blood component of human is required in
a variety of fields. The necessity is especially
important in the clinical field. Bleeding, for example
bleeding in digestive tract, occurs in a variety of
diseases. Particularly, it is well known that bleeding
from digestive tracts is an important early stage symptom
in malignant tumors of digestive tracts.
Detection of blood components in feces, especially
hemoglobin, i~ a major method currently applied to the
detection of digestive tract bleeding for diagnosis of
diseases such as malignant tumors of digestive tracts.
Reversed passive hemagglutination, latex agglutination
(fixation), gold colloid agglutination, enzyme
immunoassay, radio immunoassay, and the like are included
': .
``~ 21 761 SO
in the methods for detecting the hemoglobin in stools.
Their principle is preparing an anti-human hemoglobin~
antibody, causing an antigen-antibody reaction with
hemoglobin, and measuring or detecting the resultant by
various methods.
In the conventional immunological method for
detecting hemoglobin using the anti-human hemoglobin
antibody, however, the hemoglobin to be detected is
usually supplied to the test together with feces which
act as an inactivating factor. The antigenic determinant
of hemoglobin may be inactivated depending~on the
temperature over time, resulting in a drawback of
conspicuous deterioration of the detection sensitivity.
Hemoglobin may be denatured or decomposed,
particularly under high temperature conditions in
summertime, therefore, hemoglobin positive feces are
often reduced to negative in summer {Takefumi FUJIYOSHI
and Mariko KOYAMA, Kiso-to-Rinsho [CLINICAL REPORT (Basic
and Clinical Report)] 23(15), 6097-6101 (1989), "Basic
studies on immune stool occult blood reagent }. The
inactivation of hemoglobin is significant particularly
when its concentration is low. It is difficult to
perform hemoglobin detection which is meaningful for
diagnosis in such low concentration levels.
Development of a method for properly measuring blood
component in samples of feces or the like without being
21 76150
affected by temperatures, storage time and the like has
been required. The object of the present invention is to
provide such a method.
Disclosure of the Invention
The present inventors have conducted extensive
studies in order to detect blood or blood component in
fecal samples or the like using a blood component other
than hemoglobin.
As a result, the inventors have found that human
erythrocyte membrane band 3 glycoprotein (hereinafter
referred to as band 3) can be properly detected, because
it is much more stable than hemoglobin even in samples of
feces or the like, and forms a complex by binding with a
certain hemagglutinin specific for human erythrocytes.
This finding has led to the completion of the present
invention.
Accordingly, the present invention provides a method
for detecting a blood component in a sample comprising
reacting band 3 in the sample and a hemagglutinin
produced by a microorganlsm belonging to the genus
Conidiobol us and measuring the complex produced by the
reaction, and a kit used for the detection.
Best Mode for carryinq out the Invention
Band 3 which is detected as a blood component in the
method of the present invention is a component which has
~: 2176150
.
already been reported as an erythrocyte marker (Beppu, M.
et al., J. Biol. Chem., 256(6), 3226-3233 (1990),
"Binding of anti-band 3 autoantibody to oxidatively
damaged erythrocytes", etc.) and been studled as useful
for monitoring erythrocytes.
The hemagglutinin produced by a microorganism
belonging to the genus Conidiobolus (hereinafter
abbreviated as CA) is a human erythrocyte-specific
hemagglutinin produced by a microorganism belonging to
the genus Conidiobolus such as Conidiobolus lamprauges,
Conidiobolus nanodes, or the like. This hemagglutinin
has been reported to exhibit interactions with band 3
(Ishikawa, F. et al., Agric. Biol. Chem., 45(9), 2105-
2110 (1981), "Action of proteases on human erythrocyte
glycoproteins in relation to hemagglutination by
Conidiobolus chitin-binding agglution"), but no blood
detection method utilizing it has been known heretofore.
The method of the present invention comprises
detecting human blood component in samples by detecting
band 3 contained in a complex of band 3, which is a blood
component in that sample, and CA. Any detection methods
can be applicable inasmuch as the band 3 can be detected
in that manner.
One of the embodiments for carrying out the present
invention is a so-called sandwich method which comprises
insolubilizing CA on the surface of a solid phase, adding
21761~50
the sample and a labeled anti-band 3 antibody which
specifically binds wi,th the same band 3 to sandwich the
band 3 in the sample between the immobilized CA and the
labeled anti-band 3 antibody, and idehtifying or
measuring human blood via band 3 which has been present
in the sample.
In this embodiment, it is possible to add the
labeled anti-band 3 antibodies to the sample in advance
as mentioned below.
In the above system, a certain peptide portion of
the band 3 in the sample is recognized by an added anti-
band 3 antibody, and~sugar chain portion of the band 3 is
separately recognized and captured by the immobilized CA.
Further, another peptide portion of the band 3, which
portion is different from the peptide portion initially
recognized by the added antl-band 3 antibody, is
recognized by a labeled anti-band 3 antibody. In this
manner, the band 3 in the sample is determined by the
anti-band 3 antibody, the immobilized CA, and the labeled
anti-band 3 antibody, so that the band 3 can be highly
restricted. This prevents cross-reaction with a variety
of contaminating glycoproteins in samples resulting in an
increase of sensitivity and the specificity.
The specific detection system in the present
invention is not limlted to the above embodiments. The
21 76I50
immobilized component and the labeled component in the
above embodiments may be replaced by using a combination
of an immobilized anti-band 3 antibody~and a labeled CA,
or CA may be the immobilized component and the labeled
component as well if a combination of an immobilized CA
and a labeled CA is used. The methods similar to the
above described embodiment can be applied to these cases
for improving the sensitivity and the specificity.
Another embodiment of the method of the present
invention is a detection method using a so-called
competitive reaction. The method comprises capture of a
labeled band 3 prepared in advance by the immobilized
phase competitively along with capture of the band 3 in
the sample by the immobilized phase, whereby the presence
or absence or the quantity of blood in the sample can be
detected by the label in the former band 3.
Any labeling method, such as~radioisotope labeling,
enzyme labeling, fluorescence labeling, or light emitting
chemical labeling, can be used for labeling the CA or
anti-band 3 antibody. Specific methods include a method
of labeling with biotin and detect it by a labeled
avidin, a method of using a labeled second (other)
antibody to CA or anti-band 3 antibody instead of
labeling the CA or anti-band 3 antibody. There are no
limitations to the specific detection system inasmuch as
the labeling which enables the detection is given.
21 76150
In the method of the present invention, it i8
possible to have the anti,band 3 antibody or CA present
in the sample in advance, for example, by coating the
surface of stool collecting st1cks beforehand with a
required quantity of anti-band 3 antibody or CA in a
manner where they are capable of dissolving out.
Various buffer solutions, such as acetate buffer,
phosphate bufferj Tris-HCl buffer, glycine buffer,
ammonium buffer, borate buffer, and carbonate buffer,~are
given as examples of the base solution which solubilizes
and dissolves band 3 from samples of feces or the like
containing the same. The pH of these base solution is in
the range of 4-11.5, and preferably 4.5-8.5.
It is desirable to add sodium chloride to the base
solution to make the content of it approximately the same
as that of physiological saline. Further, it is
desirable to add sodium azide or the like in an amount of
0.05-0.5% by weight as antibacterial agent. It is also
desirable to add 0.05-2.0% by weight of bovine serum
albumin or the like as a stabilizer for proteins such as
antibodies.
Because the present invention is a method for
detecting band 3 contained in human erythrocyte membrane,
it is possible to use a surfactant as a solubilizer for
solubilizing the erythrocyte membrane for detecting the
2176150
band 3 more efficiently.
Examples of the surfactant which can be preferably
used as the solubilizer in the present invention lnclude,
but not limited to, the following surfactants.
Sodium dodecylbenzene sulfonate
. Polyoxyethylene-iso-octylphenyl ether (Triton X-100
etc.)
Polyoxyethylenenonylphenyl ether (Noident P-~40 etc.)
Polyoxyethylenesorbitol ether (Tween 20 etc.)
3-[(3-Cholamidepropyl)dimethylammonio]-1-propane
sulfonate
3-[(3-Cholamidepropyl)dimethylammonio]-2-hydroxy-1-
propane sulfonate
n-Octyl-~-D-glucopyranoside
Octanoyl-N-methylglùcamide
Nonanoyl-N-methylglucamide
Decanoyl-N-methylglucamide
n-Heptyl-~-D-thioglucoside
n-Octyl-~-D-thioglucoside
N,N-bis(3-D-gluconamidepropyl)deoxycholamide
There are no specific limitations to the method for
adding these surfactants. In the case where the above-
mentioned buffers are used as the base solution, it is
preferable to add a surfactant which can exhibit the
effect at a concentration of less than 1% by weight.
The present invention is a method discovered for the
`- : 21 761 50
first time for detecting human blood component in samples
such as feces or-the ~ike!via band 3 using CA and an
anti-band 3 antibody, and particularly advantageous as a
method for detecting fecal occult blood. As can be seen
in the examples hereinafter, the fecal occult blood can
be detected using this method at a higher sensitivity and
more stably than the conventional stool occult blood
detection method or the like using anti-hemoglobin
antibodies.
The present invention will be illustrated more
specifically referring to examples, which are not
intended to be limiting of the present invention.
Example 1
<Method for detecting band 3 in feces using an enzyme
labeled anti-band 3 antibody and CA>
(1) Purification and isolation of band 3
200 ml of O-type human blood to which an
anticoagulant was added was centrifuged at 320 x g for 10
minutes to separate plasma. The precipitate was
suspended in 200 ml of~a 0.05 M phosphate buffer (pH 7.3)
containing 1 mM EDTA, 5 mM 2-mercaptoethanol, and 0.03 mM
phenylmethylsulfonyl fluoride, adjusted to pH 7.5 with 1
M NaOH, stirred gently for 18 hours at 4C, and
centrifuged at 10,000 x g for 1 hour. The precipitate
was suspended in ice cooled water which had been adjusted
21 761 50
to pH 12 with 1 M NaOH. The suspension was stirred
gently for 30 minutes at 4C, and again centrifuged at
10,000 x g for 30 mihutes. The precipitate thus obtained
was suspended in a 40 mM Tris-HCl buffer-(pH 7.4)
containing 1~ sodium dodecyl sulfate, 2 mM EDTA and 0.04
mM 2-mercaptoethanol and allowed to stand at 4C for one
hour, following which the temperature was allowed to
raise to room temperature.
This suspension was passed through a Sepharose 6B
column (made by Pharmac~ia, 2 cm~ x 98 cm) equilibrated
with the above buffer, and fractions having absorbance at
280 nm were collected. The band 3 was eluted just before
the elution of glycofolin A.
(2) Preparation of polyclonal antibody for band 3
Band 3 was dissolved in physiological saline to
prepare a solution with a concentration of 4 mg/ml. The
solution was subcutaneously injected into back of rabbits
8 times at an interval of 2 weeks, each time at a dose of
l ml. Blood was collected 3 weeks after the final
subcutaneous injection to obtain anti-band 3 antibody
serum.
This anti-band 3 antibody serum was added to a
Protein A Sepharose CL-4B column (made by Pharmacia, 1
cm~ x 14 cm) equilibrated with a 20 mM Tris-HCl buffer
(pH 8.3) containing 0.2 M NaCl and the column was eluted
with the same buffer solution to collect fractions. The
21761 50
elution was continued until the absorbance at 280 nm
returned to the initial s,tandard level.
Next, this column was eluted with a 0.lM glycine-HCl
buffer (pH 3.0) to collect fractions until the absorbance
at 280 nm returned to the initial standard level.
Fractions which was determined to contain the protein
based on the absorbance was pooled and dialyzed against a
10 mM phosphate buffer (pH 7.5).
The antibody thus obtained was confirmed by the
Ouchterlony method to possess specificity to band 3
derived from human erythrocyte (this antibody is
hereinafter referred to as ~anti-band 3 antibody'~).
(3) Labeling the anti-band 3 antibody with an enzyme
Horse radish peroxidase (a product of Sigma Co.,
hereinafter abbreviated to HRPO) was bonded to the anti-
band 3 antibody according to the following method.
The HRPO was dissolved into a 10 mM acetate buffer
(pH 4.5) to a concentration of 15 mg/ml, and sodium
metaperiodate was added to this solution to a final
concentration of 33 mM. The mixture was incubated at
25C for 15 minutes and passed through a Sephadex G-25
column (made by Pharmacia, 1 cm~ x 14 cm) equilibrated
with the same acetate buffer as above to collect eluted
fractions with a brown color. The fraction was confirmed
to be the activated HRPO.
1i
21 7fiI 50
The activated HRPO fractions were adjusted with said
acetate buffer as above to obtain a final concentration
of 1 mg/ml. This was added to an equivalent amount of a
solution of the anti-band 3 antibody which had been
adjusted to a concentration of 4 mg/ml with a 50 mM
carbonate buffer (pH 9.5), and the mixture was incubated
at room temperature fsr 4 hours.
The reaction was retarded by the addition of sodium
borohydride to a final concentration of 2.6 mM and the
reaction was continued for 30 minutes at 4C under the
retarded conditions. The reaction of sodium borohydride
was terminated by the addition of acetone to a final
concentration of 0.2% (v/v) thus obtaining a HRPO labeled
anti-band 3 antibody.
(4) Preparation of CA
Conidiobol us lamprauges CBS 153,56 stocks were
inoculated into test tubes with an internal diameter of
16 mm, each containing 5 ml of 0.05 M phosphate buffer
(pH 7.0) containing 1% lactose, 0.5% peptone, 0.3~ yeast
extract, and 0.3% malt extract, and cultured for 3 days
at 27C on a reclprocal shàker at 120 rpm. 5 ml of the
culture broth was inoculated into each of 500 ml
Sakaguchi shaker flasks to which 100 ml of the same
phosphate buffer as above was added, and further cultured
for 5 days at 27C on a rotating shaker at 120 rpm.
The culture broth was filtered through a filter
12
- 2176150
paper to separate cells. Solid ammonium sulfate was
added to 3000 ml of the f!iltrate at 0.75 saturation with,
ice cooIing and the mixture was allowed to stand
overnight at a low temperature. The precipitate produced
was collected by centrifuge for 20 minutes at 10,000 x g,
dissolved in a 0.05 M phosphate buffer (pH 6.0), and
dialyzed against the same buffer overnight. Insoluble
matters produced were removed by centrifuge for 20
minutes at 10,000 x g, thus obtaining 142 ml of
supernatant,
This solution was passed through CM-Sephadex C-50
column (made by Sigma Co., 2 cm~ x 98 cm) equilibrated
with the same buffer as above to collect a fraction
eluted gradiently wlth 0.05-0.5 M of the above buffer
solution. Hemagglutination activity of CA of the
fraction was determined. 67 ml of this fraction was
applied to a Sepharose 4B column (made by Pharmacia., 1
cm~ x 14 cm) with ~-N-acetyl-D-glucosamine bonded and
equilibrated with a 1 M NaCl-0.05 M phosphate buffer (pH
6.0). After washing the column with the same buffer, the
column was eluted gradiently with 0-0.36 M N-
acetylglucosamine solution. Among the fractions eluted,
a portion obtained initially in the gradient elution was
used as a purified CA sample.
(5) Immobilization of CA
21:761$0
A 2 ~g/ml CA solution (0.1 mol Tris-HCl buffer, pH
8.4) was charged into a mlcroplate in an amount of 150 ~l
per well and allowed to stand overnight at 4C to adsorb
and immobilize (lnsolubilize) CA on the microplate
surface.
(6) Preparation of fecal samples
Sample 1 was prepared by mixing 2 g of feces of a
healthy adult and 8 ~1 of human blood. Sample 2 was
prepared by diluting Sample 1 to a 1/4 concentration,
i.e., by mixing about 0.5 g (1/4) of the sample with 1.5
g of the feces of the healthy adult. Sample 2 was
diluted in the same manner to a concentration of 1/4 to
prepare Sample 3 (1/16 dilution of Sample 1). Feces
containing no blood was used as a sample blank (Sample
4).
Accordingly, the amounts of blood added were 4
~1~, 0.25 ~1, and 0 ~1 per 1 g of feces.
(7) Preparation of sampling solution
A 0.1 mol/l Tris-HCl buffer solution (pH 8.0)
containing 1%~Triton X-lO0 (made by Sigma Chemical), 0.1%
sodium azide, 0.1% bovine serum albumin, and 0.9% sodium
chloride was prepared and charged to test tubes to be
used as the solution for the samples, in an amount of 2
ml per tube.
(8) Collection of samples and preparation of sample
solutions
14
, 21'7,~I50
.
Feces sampling sticks were inserted into sample
feces to collect samples,~ each about 10 mg. Each sample
was then suspended in 2 ml of the sampllng solution and
incubated at 37C for 5 minutes to prepare sample
solutions.
(9) Measurement
The immobilized CA plate obtained in (S) mentioned
above was washed with 0.1 mol Tris-HCl buffer (pH 8.4).
The sample solutions prepared in (8) were added to the
plate in an amount of 100 ~l/well, followed by the
addition of 50 ~l/well of 0.5 mol acetate buffer (pH
4.5). The mixtures were incubated at 37C for one hour
to capture band 3 in the sample solutions.
After thoroughly washing each well with a O.I mol
phosphate buffer (pH 6.8), a HRPO labeied anti-band 3
antibody solution (a solution of 1 ~g/ml HRPO labeled
anti-band 3 antibody in 0.1 mol phosphate buffer (pH 6.1)
containing 2% bovine serum albumin) was added in an
amount of 150 ~1 per well, and the mixture was incubated
at 37C for one hour.
Next, after again thoroughly washing with a 0.1 mol
phosphate buffer (pH 6.8), a substrate solution (0.05 M
acetate buffer (pH 4.5) containing 0.03% o-phenylene-
diamine and 0.01~ hydrogen peroxide) was added in an
amount of 150 ~1 per well, followed by incubation at 37C
- 21 7:61 SO
for 30 minutes. The reaction was terminated by the
addition of 50 ~l!well of 4 N hydrochloric acid.
Absorbances were measured at two wavelengths, 492 nm and
630 nm, using a spectrophotometer (a microplate reader
manufactured by Corona Co.). Band 3 in Samples 1-3
showed absorbance-of 0.5 or larger against the sample
blank, so that these were apparently positive.
Comparative Example 1
<Detection of fecal occult blood using anti-hemoglobin
antibody (conventional method)>
(1) Preparation of a latex reagent sensitized with anti-
human hemoglobin antibody
10 ml of 1 mg/ml 1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide was added to 10 ml of 5% carboxylated.
polystyrene latex and the mixture was reacted for 20
minutes while stirring. After separating out supernatant
by centrifuge, an equivalent amount (10 ml) of 0.01 mol/l
borate buffer was added to the precipitate latex. The
mixture was stirred to homogenize, centrifuged to remove
the supernatant. This procedure was repeated again, and
finally the latex was dispersed in 10 ml of said buffer
solution.
To 10 ml of the latex suspension (concentration: 5%)
was added 7 ml of anti-human hemoglobin antibody (Rabbit
IgG, concentration: 5 mg/ml), prepared by immunizing
rabbit with purified human hemoglobin Ao~ and the mlxture
16
21761S~
was reacted for 5 hours while slowly stirring. The
supernatant was removed by centrifuge. 10 ml of a 0.01
mol/l borate buffer (pH 8.0) containing 0.1~ bovine serum
albumin was added to~the precipitate latex. The mixture
was stirred and then centrifuged to remove the
supernatant. This procedure of removing supernatant by
centrifuge was repeated again. Then, after adding 10 ml
of said buffer, the mixture was stirred to obtain a latex
reagent sensitized with anti-human hemoglobin antibody
(latex concentration: 1%).
(2) Immunological latex agglutination reaction
Fecal sample solutions prepared in Example 1(8) were
placed on each serological reaction slide glass plate in
an amount of 100 ~1 each. 25 ~1 of the latex reagent as
above was added to each, and, after S minutes ~ixing with
rotation, the agglutination images were observed by naked
eyes (macroscopically). As a result, the agglutination
images were seen in Samples 1 and 2, but~not in Samples 3
and 4, indicating that the sensitivity is inferior to the
method of the present invention.
The results of Example 1 and Comparative Example l
are summarized in Table 1.
17
2176150
TABLE l
Blood !~ i' Conventional Method of
concentration method this invention
(~l/g stool) (Comp. Ex. 13 (Example l)
Sample l 4 + +
Sample 2 l + +
Sample 3 0.25 - +
Sample 4 0
-; Fecal occult blood, negative (samples exhibiting
negative agglutination reaction in the conventional
method or samples exhibiting absorbance of 0.4 or less
against the sample blank in the method of the present
invention.
+: Fecal occult blood, positive (samples exhibiting
positive agglutination reaction in the conventional
method or samples exhibiting absorbance of 0.5 or more
against the sample blank in the method of the present
invention.
Example 2
<Comparison of the present invention and conventional
method>
Sample 1, Sample 2, Sample 3, and Sample 4 (sample
blank) prepared in Example 1(7) were incubated at 37C
for 6 days, while measuring and comparing the presence of
blood by the method of the present invention in Example l
and the conventional method of Comparative Example 1
every day. The results are shown in Table 2.
18
2~176I50
TABLE 2
, Incubation at 37C (daysj
Measurement method O 1 2 3 4 5 6
Sample 1
Invention method + + + + + + -
Conventional method + +
Sample 2
Invention method + + + + +
- Conventional method +
Sample 3
Invention method + + + + -
Conventional method
Sample 4
Invention method - - - - - - -
Conventional method - - - - - - -
-; Fecal occult blood, negative (samples exhibiting
negative agglutination reaction in:the conventional
method or samples exhibiting absorbance of 0.4 or less
against the sample blank in the method of the present
invention.
+: Fecal occult bloodl positive (samples exhibiting
positive agglutination reaction in the conventional
. method or samples exhibiting absorbance of 0.5 or more
against the ~ample blank in the method of the present
invention.
The above results shows that, when incubated at
37C, according to the method of the present invention
the period of time for which a blood component can be
detected at higher sensitivity was extended by
utilization of band 3 while according to the conventional
method hemoglobin was detected for only one day or so.
19
2l 76l so
It was confirmed that stable detection was possible
according to the method 0!~ the present invention over a
long period of time even in the case where the sample was
continuously held at 37C.
Industrial Applicability
As illustrated above, according to the detecting
method of the present invention band 3 can be detected
specifically, at high sensitivity, and stably by the use
of CA. It is thus possible to qualitatively or
quantitatively detect human blood~component in feces,
contents of digestive organs, and other materials in
which the presence of human blood is questioned, or, so
detect digestive tract bleeding, occult blood in feces,
and the like, at high accuracy.
-
. 20
